Your browser doesn't support javascript.
loading
Predictors of Successful First-Line Helicobacter pylori Eradication with Fluoroquinolones in Pakistan: A Prospective Exploration of Demographic and Clinical Factors.
Khadim, Sumaira; Muhammad, Iyad Naeem; Alam, Tanveer; Usman, Shahnaz; Rehman, Hina; Haider, Sajjad.
Afiliación
  • Khadim S; Faculty of Health Sciences, Iqra University of Health Sciences, Karachi 75500, Pakistan.
  • Muhammad IN; Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, Karachi 75270, Pakistan.
  • Alam T; Jamal Noor Hospital, Karachi 74800, Pakistan.
  • Usman S; RAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
  • Rehman H; Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University, Karachi 75510, Pakistan.
  • Haider S; Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, Karachi 75270, Pakistan.
Antibiotics (Basel) ; 13(3)2024 Feb 23.
Article en En | MEDLINE | ID: mdl-38534646
ABSTRACT
Growing antibiotic resistance complicates H. pylori eradication, posing a public health challenge. Inconclusive research on sociodemographic and clinical factors emphasizes the necessity for further investigations. Hence, this study aims to evaluate the correlation between demographic and clinical factors and the success rates of H. pylori eradication. A group of 162 H. pylori-positive patients were allocated randomly to receive either a ten-day moxifloxacin-based triple therapy or a levofloxacin-based sequential therapy. Eradication success was determined through the stool antigen test. Logistic regression analysis was utilized to figure out potential factors that contribute to H. pylori eradication success. Significantly higher H. pylori eradication rates were observed in the middle age group (COR 3.671, p = 0.007), among females (p = 0.035), those with BMI ≥ 25 (COR 2.011, p = 0.045), and non-smokers (COR 2.718, p = 0.018). In multivariate analysis, age and smoking emerged as significant predictors (p < 0.05). Patients with comorbidities, excluding diabetes and hypertension (COR 4.432, p = 0.019), dyspepsia (COR 0.178, p < 0.001), and moxifloxacin triple therapy (COR 0.194, p = 0.000), exhibited higher chances of eradication (p < 0.05). Further research is vital for tailored approaches to enhance eradication success.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Antibiotics (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Antibiotics (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Suiza